Lv562
1008 积分 2022-06-23 加入
Pembrolizumab in HER2-Positive Gastric Cancer
2天前
已完结
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
2天前
已完结
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
24天前
已完结
Novel strategy for a bispecific antibody: induction of dual target internalization and degradation
28天前
已完结
Esophageal Cancer: A Historical Perspective
1个月前
已完结
The safety of trastuzumab deruxtecan (DS‐8201) with a focus on interstitial lung disease and/or pneumonitis: A systematic review and single‐arm meta‐analysis
1个月前
已完结
High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database
1个月前
已完结
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
1个月前
已完结
HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis
1个月前
已完结
皖公网安备34019202002308
